Somatostatin analogue treatment of neuroendocrine tumours (Q38644664)

5 September 2017

1 reference

title

Somatostatin analogue treatment of neuroendocrine tumours (English)

1 reference

5 September 2017

W W de Herder

1

1 reference

5 September 2017

A J van der Lely

series ordinal

2

1 reference

5 September 2017

S W Lamberts

series ordinal

3

1 reference

5 September 2017

language of work or name

English

0 references

publication date

1 July 1996

1 reference

Postgraduate Medical Journal

5 September 2017

1 reference

5 September 2017

72

1 reference

5 September 2017

849

1 reference

5 September 2017

403-408

1 reference

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

5 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Therapeutic considerations for the malignant carcinoid syndrome

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Neuroendocrine embryology and the APUD concept

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Somatostatin (second of two parts).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Current tools in the diagnosis of pituitary tumours.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Effect of a somatostatin analog (SMS 201-995) in perfusion on basal and pentagastrin-stimulated calcitonin levels in medullary thyroid carcinoma

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995).

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Karnofsky memorial lecture. An odyssey in the land of small tumors.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

Neuroendocrine-immune interactions.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2398518

31 August 2018

1 reference

12 December 2020

Octreotide treatment of acromegaly. A randomized, multicenter study

1 reference

12 December 2020

Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2, and -3 in patients with acromegaly before and after adenomectomy

1 reference

12 December 2020

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

1 reference

12 December 2020

Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995)

1 reference

12 December 2020

Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly

1 reference

12 December 2020

Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro

1 reference

12 December 2020

Metastatic carcinoid tumors and the malignant carcinoid syndrome

1 reference

12 December 2020

The use of octreotide in the treatment of medullary thyroid carcinoma

1 reference

12 December 2020

A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome

1 reference

12 December 2020

Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas

1 reference

12 December 2020

Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion

1 reference

12 December 2020

Identifiers

DOI

10.1136/PGMJ.72.849.403

1 reference

5 September 2017

1 reference

5 September 2017

1 reference